Results 61 to 70 of about 11,372 (280)

Are We Ready for Nosocomial Candida auris Infections? Rapid Identification and Antifungal Resistance Detection Using MALDI-TOF Mass Spectrometry May Be the Answer

open access: yesFrontiers in Cellular and Infection Microbiology, 2021
The occurrence of multidrug-resistant Candida auris isolates and the increased mortality associated with invasive infections or outbreaks due to this Candida species have been reported in many healthcare settings.
Elena De Carolis   +8 more
doaj   +1 more source

Anidulafungin for Candida glabrata Infective Endocarditis [PDF]

open access: yesAntimicrobial Agents and Chemotherapy, 2012
Sir, we briefly report on a patient with infective endocarditis (IE) by Candida glabrata treated with double-dosage of anidulafungin.…
DE ROSA, Francesco Giuseppe   +8 more
openaire   +4 more sources

Parallel and cross-resistances of clinical yeast isolates determined by susceptibility pattern analysis

open access: yesGMS Infectious Diseases, 2016
For calculated initial antifungal therapy, knowledge on parallel and cross-resistances are vitally important particularly in the case of multiresistant isolates.
Schmalreck, Arno F.   +6 more
doaj   +1 more source

The conundrum of antifungal resistance: Emergence of Nakaseomyces glabratus (Candida glabrata) in Europe with global implications. [PDF]

open access: yesJ Eur Acad Dermatol Venereol
Journal of the European Academy of Dermatology and Venereology, Volume 39, Issue 2, Page 255-256, February 2025.
Gupta AK, Wang T.
europepmc   +2 more sources

Anidulafungin induced reversible thrombocytopenia in a patient: A case report

open access: yesMedicine Science, 2018
Anidulafungin is a semisynthetic antifungal agent which is an echinocandin. Here, we presented elderly patient developed reversible severe thrombocytopenia due to anidulafungin.
Zubeyir Cebeci   +3 more
doaj   +1 more source

Anidulafungin liposome nanoparticles exhibit antifungal activity against planktonic and biofilm Candida albicans.

open access: yesJournal of Biomedical Materials Research. Part A, 2020
Fungal infections can cause significant patient morbidity and mortality. Nanoparticle therapeutics have the potential to improve treatment of these infections.
Noel Vera-González   +6 more
semanticscholar   +1 more source

Invasive pulmonary aspergillosis post extracorporeal membrane oxygenation support and literature review [PDF]

open access: yes, 2014
The use of extracorporeal membrane oxygenation (ECMO) for reversible pulmonary failure in critically ill patients has increased over the last few decades.
Al-Shair   +18 more
core   +2 more sources

The seizure of illicit assets: patterns of civil forfeiture in Canada and Ireland [PDF]

open access: yes, 2013
No description ...
Gallant, M Michelle, King, Colin
core   +1 more source

Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis - review of the literature

open access: yesEuropean Journal of Medical Research, 2011
Echinocandins represent the newest class of antifungal agents. Currently, three echinocandins, anidulafungin, caspofungin and micafungin are licensed for clinical use in various indications.
Kofla G, Ruhnke M
doaj   +1 more source

Flash pulmonary oedema during anidulafungin administration

open access: goldJournal of Clinical Pharmacy and Therapeutics, 2011
Anidulafungin is an echinocandin antifungal used to treat invasive fungal infections caused by Candida or Aspergillus species. While the echinocandins are generally well tolerated, novel adverse reactions may occur. Specifically, echinocandins have been associated with histamine-mediated infusion reactions.
C. B. Hindahl, John Wilson
openalex   +4 more sources

Home - About - Disclaimer - Privacy